PENTASA Drug Patent Profile
✉ Email this page to a colleague
When do Pentasa patents expire, and when can generic versions of Pentasa launch?
Pentasa is a drug marketed by Takeda Pharms Usa and is included in one NDA.
The generic ingredient in PENTASA is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pentasa
A generic version of PENTASA was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PENTASA?
- What are the global sales for PENTASA?
- What is Average Wholesale Price for PENTASA?
Summary for PENTASA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 181 |
| Clinical Trials: | 25 |
| Patent Applications: | 4,188 |
| Drug Prices: | Drug price information for PENTASA |
| Drug Sales Revenues: | Drug sales revenues for PENTASA |
| What excipients (inactive ingredients) are in PENTASA? | PENTASA excipients list |
| DailyMed Link: | PENTASA at DailyMed |
Recent Clinical Trials for PENTASA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bogomolets National Medical University | N/A |
| Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine | N/A |
| HIV Immunotherapeutics Institute | Phase 1/Phase 2 |
Pharmacology for PENTASA
| Drug Class | Aminosalicylate |
US Patents and Regulatory Information for PENTASA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | PENTASA | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 020049-001 | May 10, 1993 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Takeda Pharms Usa | PENTASA | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 020049-002 | Jul 8, 2004 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PENTASA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | PENTASA | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 020049-001 | May 10, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Takeda Pharms Usa | PENTASA | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 020049-001 | May 10, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PENTASA
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
